DN
Therapeutic Areas
Siga Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TPOXX (tecovirimat) | Treatment of Smallpox | Approved |
| TPOXX for PEP | Post-Exposure Prophylaxis for Smallpox | Phase 3 / Development |
| TPOXX Pediatric Formulation | Oral Liquid Suspension for Smallpox (patients <13 kg) | Development |
Leadership Team at Siga
DJ
Daniel J. Luckshire, M.B.A.
Executive Vice President and Chief Financial Officer
DE
Dennis E. Hruby, Ph.D.
Executive Vice President and Chief Scientific Officer
LM
Larry Miller
General Counsel
JD
Jaymie Durnan
Board Member
HF
Harold Ford, Jr.
Board Member
GJ
GEN John M. “Jack” Keane (Ret.)
Board Member
JW
Joseph W. “Chip” Marshall III
Board Member
DG
Dr. Gary Nabel
Board Member